# Howard Davis

> Howard Davis, Ph.D., is the CEO of Akamis Bio, a clinical-stage oncology company in Cambridge, Massachusetts building tumor gene therapies on its proprietary T-SIGn platform. A chemical engineer turned biomedical engineer, he spent two decades moving between Boston Consulting Group, Novartis, Biogen, Flagship Pioneering and Atlas Venture before taking the top job at the company once known as PsiOxus. His current mission: prove that an adenoviral therapy delivered through a vein - not a needle into the tumor - can reach metastatic cancer the body has hidden, and turn those tumors against themselves.

- **Role:** Chief Executive Officer at Akamis Bio
- **Organizations:** Akamis Bio, Third Harmonic Bio, Flagship Pioneering, Biogen, Novartis, Boston Consulting Group
- **Nationality:** American
- **Education:** B.S. in Chemical Engineering, Yale University, Ph.D. in Biomedical Engineering, Harvard-MIT Division of Health Sciences & Technology
- **Known for:** Led Akamis Bio's $60M Series A financing, Secured a Greater China licensing partnership for NG-350A with Xuanzhu Biopharma, As COO of Third Harmonic Bio, spearheaded fundraising that secured $155M in private financing

## Career timeline

- **Early career** — Began industry career in the healthcare practice at Boston Consulting Group
- **Pharma years** — Held roles of increasing responsibility at Novartis and Biogen across commercial, manufacturing, pipeline program leadership and corporate strategy; at Biogen served as VP and asset executive for gosuranemab
- **Flagship** — Principal at Flagship Pioneering, focused on corporate strategic partnerships and new company creation
- **2022** — Worked with Atlas Venture on the launch of Third Harmonic Bio; as COO secured $155M in private financing for its lead molecule
- **2022-07** — Appointed CEO and board member of PsiOxus Therapeutics (later renamed Akamis Bio)
- **2024** — Akamis Bio raised $60M Series A led by Sedgwick Yard and signed a Greater China licensing deal for NG-350A with Xuanzhu Biopharma

## Achievements

- Led Akamis Bio's $60M Series A financing
- Secured a Greater China licensing partnership for NG-350A with Xuanzhu Biopharma
- As COO of Third Harmonic Bio, spearheaded fundraising that secured $155M in private financing
- Rebranded PsiOxus Therapeutics as Akamis Bio and refocused the pipeline on T-SIGn tumor gene therapy

## Latest updates

- **2024-12** — Akamis Bio's most recently reported raise: $60M Series A financing (Series A), supporting advancement of NG-350A through the FORTRESS study.

## Links

- Website: https://akamisbio.com
- LinkedIn: http://www.linkedin.com/in/howard-e-davis-ph-d-5117b1

---

Profile page: https://yespress.io/howard-davis
Published by YesPress — https://yespress.io
Last updated: 2026-06-04